Marieke van Son

93 MRI-GUIDED ULTRAFOCAL SALVAGE HDR-BRACHYTHERAPY Figure 2 shows patient-reported urinary and erectile function (IPSS and IIEF-5). For the IPSS, score 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms. Median baseline score was 8, increasing to a median 11.5 at one month follow-up and then returning back to baseline level (median 8 at 36 months follow-up). For the IIEF-5, score 1-7 indicates severe ED, 8-11 indicatesmoderate ED, 12-16 indicates mild to moderate ED, 17-21 indicates mild ED, and 22-25 indicates absence of ED. Median baseline score was 11, which quickly deteriorated to a median 7 after the first month, with a further downward trend to median 3 at 36 months follow-up. Out of 13 patients with pre-treatment potency (here defined as IIEF≥17), five patients (38%) remained potent. Figure 2 – Patient-reported toxicity. Medians with interquartile ranges (IQR) and complete ranges are shown. The blue dots represent outliers, defined as >1.5 * IQR. a) IPSS (urinary symptoms), b) IIEF-5 (erectile function). QoL Patient-reported QoL over time is depicted in supplementary figures 1-3 (available online at https://doi.org/10.1016/j.ijrobp.2020.01.023) , with separate graphs for the different domains within each questionnaire. Within the general health survey (RAND-36), long-term clinically relevant deteriora- tion of QoL was seen in the domains social functioning (Δ13 points) and mental health (Δ12 points). Patients reported a transient increase in pain symptoms (Δ11 points) after three months follow-up, which recovered afterwards. No statistically significant changes were seen. Regarding cancer-related health (EORTC QLQ-C30), the domains tiredness and cog- nitive functioning showed long-term clinically relevant deterioration (Δ11 and 17 points, respectively). A transient increase of sleeping disturbances (Δ33 points) was seen at 24 months follow-up. Again, no statistically significant changes were observed. 5